Number of rare invasive fungal infection (IFI) are rising worldwide due to increasing patient population at risk. To broaden knowledge on epidemiology of emerging IFD, FungiScope a global registry has been initiated. Currently, partners from 63 countries contribute cases that eventually help determining clinical patterns, improve diagnostic procedures and therapeutic regimens.
FungiScope uses web-based data capture accessible through www.fungiscope.net. For case enrollment, cultural, histological, antigen or molecular evidence on the occurrence of infection with non-endemic fungi is required. Data collected include demographics, underlying conditions, immunosuppressive medication, clinical signs and symptoms, sites of infection, diagnostic tests, pathogen identification, antifungal treatment and outcome. Clinical isolates are collected for centralized identification, molecular analyses and exchange between collaborators.
To date, 478 cases have been captured. Mucorales (n=208; 43.5%), Fusarium spp. (n=71; 14.8%), yeasts (n=65; 13.6%), and dematiaceae (n=52; 10.8%) are the most frequently registered pathogens. Chemotherapy (n=216; 45.2%) and stem cell transplantation for hematological malignancy (n=114; 23.8%) were the predominant risk factors, followed by intensive care (n=102; 21.34%), diabetes mellitus (n=95; 19.9%), and chronic renal disease (n=39; 8.2%). For 26 cases (5.4%) no risk factor was identified. Major sites of infection included lung (n=240; 40.2%), paranasal sinuses (n=86; 18%), blood stream (n=92; 19.3%), and deep soft tissue (n=71; 14.9%). Disseminated infection (n=72; 16.8%), including blood stream infections, was mostly associated with lung (n= 94; 58.8%) and CNS involvement (n= 30; 18.8%). For 237 (53%) patients, complete or partial response to treatment of IFD was documented. All-cause-mortality and mortality attributable to IFD was 45.8% and 34%, respectively.
The clinical relevance of emerging IFD is increasing. FungiScope is a vividly expanding network that attained increasing interest throughout the years. In a short time period, a wide variety of cases has been collected that provide a comprehensive view on the epidemiology and clinical presentation of rare IFI.
M. Vehreschild, MSD/Merck: Consultant and Speaker's Bureau , Consulting fee and Speaker honorarium
Gilead Sciences: Speaker's Bureau , Speaker honorarium
Astellas Pharma: Consultant , Research Contractor and Speaker's Bureau , Consulting fee , Research support and Speaker honorarium
B. Liss, None
P. Köhler, Astellas Pharma: Speaker's Bureau , Speaker honorarium
H. Wisplinghoff, None
J. J. Vehreschild, None
O. Cornely, Astellas Pharma: Consultant , Grant Investigator and Speaker's Bureau , Consulting fee , Grant recipient and Speaker honorarium
Basilea: Consultant , Grant Investigator and Speaker's Bureau , Consulting fee , Grant recipient and Speaker honorarium
Gilead Sciences: Consultant , Grant Investigator and Speaker's Bureau , Consulting fee , Grant recipient and Speaker honorarium
Merck/MSD: Consultant , Grant Investigator and Speaker's Bureau , Consulting fee , Grant recipient and Speaker honorarium
Pfizer: Consultant and Grant Investigator , Consulting fee , Grant recipient and Speaker honorarium
See more of: Poster Abstract Session